Overall, a model emerges from our results whereby HuR SUMOylation may be controlling the translation of mRNAs involved in the SUMO pathway eventually modulating the number of SUMO-conjugated proteins, including HuR itself, which could be playing a role in HCC progression. This evidence concerns the gene ELAVL1 and hepatocellular carcinoma.